Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals. It is currently in the early phases of review by the United States' Food and Drug Administration and, if approved, it will be available approximately in 2008.

Selective estrogen receptor modulators undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis.